| 1.18 0.269 (29.56%) | 11-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.34 | 1-year : | 3.38 |
| Resists | First : | 2 | Second : | 2.9 |
| Pivot price | 0.86  |
|||
| Supports | First : | 0.56 | Second : | 0.46 |
| MAs | MA(5) : | 0.92 |
MA(20) : | 0 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | 0 | Signal : | 0 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 41.2 |
|||
| 52-week | High : | 1.75 | Low : | 0.56 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ALPS ] has closed below upper band by 11.0%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 1.18 - 1.19 | 1.19 - 1.19 |
| Low: | 0.9 - 0.91 | 0.91 - 0.91 |
| Close: | 1.17 - 1.18 | 1.18 - 1.19 |
Alps Group Inc is an integrated biotechnology platform providing research and development, medical services, and wellness solutions focused on advanced therapies. The company aims to create a fair healthcare ecosystem with accessible predictive, preventive, and precision medicine.
Thu, 06 Nov 2025
Alps Group Inc. Rings the Closing Bell - Nasdaq
Tue, 04 Nov 2025
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.56% - Investing.com
Tue, 04 Nov 2025
Dow Dips Over 400 Points; Pfizer Earnings Top Estimates - Benzinga
Mon, 03 Nov 2025
Gold Edges Higher; ISM Manufacturing PMI Falls In October - ALPS Group (NASDAQ:ALPS), Alvotech (NASDAQ:ALVO) - Benzinga
Mon, 03 Nov 2025
Nasdaq Surges 1%; ON Semiconductor Posts Upbeat Q3 Earnings - Benzinga
Fri, 31 Oct 2025
Alps Group (NASDAQ: ALPS) begins trading after business combination; est. $1.6B EV - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|